Recent Trial Suggests Johnson & Johnson Vaccine Is Effective Against Delta Variant
A study being conducted by South Africa’s Ministry of Health found that a single dose of the Johnson and Johnson vaccine could potentially prevent severe illness and death from the highly transmissible Delta and Beta variants.
The trial called Sisonke evaluated a pool of nearly 500,000 health care workers who had received a single dose of the Johnson & Johnson vaccine. Studies found that the vaccine had a 95 percent efficacy rate against the Delta Variant “and up to 71 percent against hospitalization” the New York Times notes. However, the findings revealed that the vaccine wasn’t able to fare against the Beta strain which is becoming increasingly harder to fight off from infection–even amongst the vaccinated.
According to a report from CNBC, the variant contains “several significant mutations to the virus’ spike protein —E484K, K417N, and N501Y — that make it easier for this variant to infect people, as well as potentially making it harder to treat, or to prevent with Covid vaccines.”
The WHO announced back in July that while the vaccines offer protection against “severe disease” there is “possible reduced protection against symptomatic disease and infection.”
https://www.yahoo.com/lifestyle/recent-trial-suggests-johnson-johnson-144228986.html
